Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 1764.

https://doi.org/10.1182/blood-2019-125626

Published: 2019

Journal Articles

Frequency Of NOTCH1 Mutations In Brazilian Patients With CLL

Paulo Vidal Campregher, MD, Roberta Cardoso Petroni, Nair Muto, PhD, Juliana Nogueira M. Rodrigues, Roberta Sitnik, PhD, Nydia Bacal, MD, Gislaine Borba Oliveira, MD,, Rubia Santana, Irene L Metze, MD, PhD, Carlos S Chiattone, MD, PhD, Nelson Hamerschlak, MD, PhD

Blood (2013) 122 (21): 5291.

https://doi.org/10.1182/blood.V122.21.5291.5291

Published: 2013

Journal Articles

Associations Of VEGF and VEGFR2 Polymorphisms With Increased Risk and Aggressiveness Of Multiple Myeloma

Angelo Borsarelli Carvalho Brito, Leisa Lopes Aguiar, Gislaine Borba Oliveira, MD, Gustavo Jacob Lourenco, PhD, Carmino Antonio De Souza, José Vassallo, MD, PhD, Carmen Silvia Passos Lima, MD, PhD

Blood (2013) 122 (21): 1886.

https://doi.org/10.1182/blood.V122.21.1886.1886

Published: 2013

Journal Articles

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Beatriz F Ribeiro, Eliana C M Miranda, MEd, Marcia T Delamain, MD, Gislaine Borba Oliveira, MD,, Maria Helena Almeida, RN, Vagner O Duarte, Irene L Metze, MD, PhD, Carmino A De Souza, Sr., MD, PhD, Rosana A Silveira, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 5189.

https://doi.org/10.1182/blood.V122.21.5189.5189

Published: 2013

Journal Articles

Novel Assay for the Identification of NOTCH1 PEST Domain Mutations Using Fragment Analysis and Allele Specific PCR

Paulo Vidal Campregher, MD, Roberta Cardoso Petroni, Nair Muto, PhD, Rubia Santana, Roberta Sitnik, PhD, Oziris P S Ramos, Nydia Bacal, MD, Carolina B Bub, MD, Fabio P S Santos, MD, Perini Guilherme, MD, Helman Ricardo, MD, Clarissa Souza, MD, Reijane Alves de Assis, MD, Gislaine Borba Oliveira, MD, Irene L Metze, MD, PhD, Nelson Hamerschlak, MD, PhD

Blood (2012) 120 (21): 5127.

https://doi.org/10.1182/blood.V120.21.5127.5127

Published: 2012

Journal Articles

The Utilization of NET Promoter System As a Blood Supply Management Strategy

Gustavo De Carvalho Duarte, MD, Erich V de Paula, MD, PhD, Francisco J P Aranha, MD, PhD, Gislaine Borba Oliveira, MD, Afonso Celso Vigorito, MD, PhD, Carmino Antonio De Souza, MD, PhD, José Francisco Marques, PhD

Blood (2012) 120 (21): 4378.

https://doi.org/10.1182/blood.V120.21.4378.4378

Published: 2012

NARROW

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Frequency Of NOTCH1 Mutations In Brazilian Patients With CLL

Associations Of VEGF and VEGFR2 Polymorphisms With Increased Risk and Aggressiveness Of Multiple Myeloma

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Novel Assay for the Identification of NOTCH1 PEST Domain Mutations Using Fragment Analysis and Allele Specific PCR

The Utilization of NET Promoter System As a Blood Supply Management Strategy

Email alerts

ASH Publications

American Society of Hematology

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Frequency Of NOTCH1 Mutations In Brazilian Patients With CLL

Associations Of VEGF and VEGFR2 Polymorphisms With Increased Risk and Aggressiveness Of Multiple Myeloma

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Novel Assay for the Identification of NOTCH1 PEST Domain Mutations Using Fragment Analysis and Allele Specific PCR

The Utilization of NET Promoter System As a Blood Supply Management Strategy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only